Literature DB >> 29880625

Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.

Grace Elizabeth Dolman1, Paul Selby2, William T Gelson1.   

Abstract

The era of direct acting antivirals has revolutionised the management of chronic hepatitis C infection and improved patient outcomes. The optimal management of patients who require liver transplantation remains a matter of ongoing discussion. Treatment in the post-transplantation setting may be complicated by significant drug-drug interactions between antiviral agents and standard immune suppressive treatment regimens. We describe what we believe to be the first reported case of a patient successfully treated for CHC with ombitasvir/paritaprevir/ritonavir plus dasabuvir, while taking sirolimus following liver transplantation. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drug interactions; drugs: infectious diseases; hepatitis C; hepatitis and other Gi infections; transplantation

Mesh：

Substances：

Year:  2018        PMID： 29880625      PMCID： PMC6011507          DOI： 10.1136/bcr-2018-224664

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.

Authors:  Surakit Pungpapong; Bashar Aqel; Michael Leise; K Tuesday Werner; Jennifer L Murphy; Tanisha M Henry; Kristen Ryland; Amy E Chervenak; Kymberly D Watt; Hugo E Vargas; Andrew P Keaveny
Journal:  Hepatology       Date:  2015-04-27       Impact factor: 17.425

2.  Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.

Authors:  Kerstin Herzer; Tania M Welzel; Ulrich Spengler; Holger Hinrichsen; Hartwig Klinker; Thomas Berg; Peter Ferenci; Markus Peck-Radosavljevic; Akin Inderson; Yue Zhao; Maria Jesus Jimenez-Exposito; Stefan Zeuzem
Journal:  Transpl Int       Date:  2017-03       Impact factor: 3.782

3.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

4.  Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.

Authors:  Caroline Barau; P Blouin; Caroline Creput; A M Taburet; Antoine Durrbach; Valérie Furlan
Journal:  Fundam Clin Pharmacol       Date:  2009-08       Impact factor: 2.748

5.  Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

Authors:  R Flisiak; E Janczewska; M Wawrzynowicz-Syczewska; J Jaroszewicz; D Zarębska-Michaluk; K Nazzal; B Bolewska; J Bialkowska; H Berak; K Fleischer-Stępniewska; K Tomasiewicz; K Karwowska; K Rostkowska; A Piekarska; O Tronina; G Madej; A Garlicki; M Lucejko; A Pisula; E Karpińska; W Kryczka; A Wiercińska-Drapało; I Mozer-Lisewska; M Jabłkowski; A Horban; B Knysz; M Tudrujek; W Halota; K Simon
Journal:  Aliment Pharmacol Ther       Date:  2016-09-09       Impact factor: 8.171

6.  Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

Authors:  Michael Charlton; Edward Gane; Michael P Manns; Robert S Brown; Michael P Curry; Paul Y Kwo; Robert J Fontana; Richard Gilroy; Lewis Teperman; Andrew J Muir; John G McHutchison; William T Symonds; Diana Brainard; Brian Kirby; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Didier Samuel; Xavier Forns; Norah A Terrault
Journal:  Gastroenterology       Date:  2014-10-07       Impact factor: 22.682

7.  Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Authors:  P Badri; S Dutta; E Coakley; D Cohen; B Ding; T Podsadecki; B Bernstein; W Awni; R Menon
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086

8.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.